The Alzeca Advantage
Alzeca is developing a proprietary intravenous contrast agent that targets Alzheimer’s disease pathology. To date, our targeted agent has shown the ability to detect early stage disease pathology with exceptional resolution and sensitivity using commonly available imaging techniques. Its development was initiated through a collaboration between Dr. Ananth Annapragada and Dr. Jason Eriksen at Texas Children’s Hospital and the University of Houston, respectively. Key advances in the development of this targeted agent have been supported by private investors and grants from the NIH, Cure Alzheimer’s Fund, Alzheimer’s Association, and The Alliance for NanoHealth.
- A Novel Liposomal Nanoparticle for the Imaging of Amyloid Plaque by Magnetic Resonance Imaging. Tanifum EA, Ghaghada K, Vollert C, Head E, Eriksen JL, Annapragada A. J Alzheimers Dis. 2016 Mar 25. PMID:27031484
- Cerebral vascular leak in a mouse model of amyloid neuropathology. Tanifum EA, Starosolski ZA, Fowler SW, Jankowsky JL, Annapragada AV.J Cereb Blood Flow Metab. 2014 Oct;34(10):1646-54. doi: 10.1038/jcbfm.2014.125. Epub 2014 Jul 23. PMID: 25052555
- Intravenous delivery of targeted liposomes to amyloid-β pathology in APP/PSEN1 transgenic mice. Tanifum EA, Dasgupta I, Srivastava M, Bhavane RC, Sun L, Berridge J, Pourgarzham H, Kamath R, Espinosa G, Cook SC, Eriksen JL, Annapragada A. PLoS One. 2012;7(10):e48515. doi: 10.1371/journal.pone.0048515. Epub 2012 Oct 31. PMID: 23119043.
Intellectual Property Notice
The proprietary contrast agents and method of using same described on this site are protected by patents in the U.S. and elsewhere. Additional patents are pending. This page is intended to serve as notice under 35 U.S.C. § 287(a).
U.S. Patent Nos. 7,785,568 | 8,357,351 | 8,642,013 | 8,911,708 | 9,744,251
For questions about Alzeca Biosciences, Inc.’s intellectual property rights, please contact [email protected]